Red Flags in Stem Cell Marketing: A Reader's Field Guide (2026)

One reads regenerative-medicine marketing copy the way one reads a Causeway Bay luxury catalogue — slowly, sceptically, with an eye on the seams. The better Gangnam practices, in my reading across the older Cheongdam and Apgujeong corridors, write modestly; the louder copy is, more often than not, signalling something a careful reader should attend to. What follows is a field guide to ten patterns of claim — categorical rather than directed at any specific practice — that a thoughtful patient should pause over before the consult is booked. 慢慢睇清楚, as the Cantonese phrasing has it. The cleaner copy reads quietly.

How we read the copy — methodology and editorial constraints

The list below is an editorial reading of marketing-copy patterns rather than a directory of practices, and the distinction governs how a reader should use it. The patterns were drawn from three sources of evidence: a comparative reading of regenerative-medicine marketing copy across the Korean, Japanese, Taiwanese, Singaporean, and United States markets in the relevant registers; a sustained reading of the conservative Korean medical-aesthetic literature on what the cleaner consults treat as routine versus what they treat as departure from the protocol's discipline; and the regulatory framework governing healthcare advertising in Korea — the Medical Service Act's Article 56 and its calibration of foreign-patient marketing copy in particular — which itself articulates a register the conservative practices stay well inside. No practice is named in what follows, and no practice is positioned against another. Korean medical-tourism law (Article 56(4) of the Medical Service Act) treats direct ranking and named comparison of healthcare providers in foreign-patient contexts as a regulated matter, and the editorial register here is calibrated accordingly. What the list offers is a categorical framework — patterns of claim that a careful reader should pause over, regardless of the practice the copy belongs to — rather than a list of practices to avoid. The reading is intentionally restrained; the better Gangnam consult rooms read the same way, and the framework is meant to mirror that disposition. Patients should treat the list as a reading lens for the marketing materials they encounter rather than as a screening tool against any specific practice. The framework is the spine; the consult is the stress test.

• Comparative reading of regenerative-medicine copy across five markets
• Conservative Korean medical-aesthetic literature on consult discipline
• Korean Medical Service Act Article 56 framework on healthcare advertising
• Editorial register calibrated to the regulatory framework

#1 — Promises of guaranteed outcomes

The first pattern, and one of the cleaner ones to read, is the language of the guarantee. Cellular therapy is — by the conservative reading of the regenerative-medicine literature, and by the register the older Korean practices sustain — a probabilistic intervention. Outcomes vary across indications, across patient subgroups, across cellular preparations, and across the systemic-medicine context the protocol intersects with. A practice's marketing copy that frames the cellular protocol as guaranteed, as 100-per-cent effective, as 'permanent', or as the cellular equivalent of a procedural certainty is, in my reading, working under thinner discipline than the indication requires. The cleaner Korean practices write in the register of probability — 'patients report', 'may help', 'studies suggest', 'in the relevant indications' — and the register is itself a marker. The guarantee register does the opposite work; it compresses the indication's variability into a marketing-grade promise. Patients should pause when the copy reads as procedural rather than as probabilistic. The pause is the practice's first stress test.

Patterns to watch for: - 'Guaranteed results' or 'guaranteed outcomes' in the marketing copy - 'Permanent' as a frame for any cellular protocol's effect - 'Money-back guarantee' on a clinical protocol — outside the cancellation framework - Outcome promises framed without indication, stage, or cellular-preparation calibration

Why it reads as a flag: The conservative regenerative-medicine register treats outcome variability as protocol-defining; copy that erases the variability is signalling a thinner clinical disposition than a careful patient should accept. A useful diagnostic question — one a careful reader can carry into any consult — is whether the practice can articulate, in patient-readable language, the published response-rate range for the indication in question; the practices that can are working in the cleaner register, and the practices that cannot are working at the marketing-grade promise the copy delivers.

#2 — Celebrity endorsements without disclosure

The second pattern reads in the marketing copy's relationship to the celebrity register. Korean medical-aesthetic culture sits inside a celebrity-economy that is, in my reading, denser than most adjacent markets — the K-pop, K-drama, and Korean lifestyle-media registers all intersect with the medical-aesthetic corridor more substantively than they do in Hong Kong, Singapore, or the United States. The cleaner Korean practices treat the celebrity intersection with restraint; the Cheongdam consult rooms host the celebrity register quietly rather than performing it. A practice's marketing copy that foregrounds celebrity endorsements — particularly without articulating the commercial relationship that underwrites the endorsement, the indication the celebrity was treated for, or the protocol calibration in question — is, on the conservative reading, doing the marketing work the protocol's evidence base should be doing. The Korea Fair Trade Commission framework on commercial-relationship disclosure articulates an expectation the cleaner practices meet routinely; the practices that compress the celebrity register into testimony without disclosure are working at a register a careful reader should pause over.

Patterns to watch for: - Celebrity images foregrounded without commercial-relationship disclosure - Celebrity 'testimonials' without indication, stage, or protocol calibration - Influencer partnerships framed as patient testimony - Celebrity-treatment claims that a careful reader cannot verify against the public record

Why it reads as a flag: The cleaner Korean medical-aesthetic register treats the celebrity intersection with restraint; copy that performs the intersection without disclosure is signalling marketing-led rather than indication-led practice. The Korea Fair Trade Commission's [advertising-disclosure framework](https://www.ftc.go.kr/eng/) articulates the disclosure register the conservative practices sustain. A related caution — and one that travels across the Hong Kong, Singaporean, and Taiwanese reader's experience as readily as the Korean — is the user-generated-content register that imports influencer testimony into the practice's marketing copy without any disclosure of the commercial relationship that underwrites the testimony; the cleaner copy reads the user-generated register the way it reads the celebrity register, with disclosure at the centre rather than at the footnote.

#3 — Unverifiable cell counts and proprietary processing

The third pattern reads in the cellular-product copy itself. Cellular therapy depends, in its mechanism, on the cellular product — its source, its preparation, its quality-control register, its lot identification. The conservative Korean practices articulate the cellular product's parameters with reference to the regulatory framework, the published literature, and the laboratory's documented quality-management infrastructure. A practice's marketing copy that names a cell count — 'one billion mesenchymal cells', 'a hundred million stem cells per dose' — without articulating the counting methodology, the published reference range, the laboratory's quality-control register, or the registration framework the cellular product sits within is, in the cleaner reading, performing precision rather than substantiating it. The marketing-grade cell count is, on a careful reading, one of the most diagnostic of the unverifiable claim patterns. A related pattern is the proprietary-processing claim — 'our exclusive cellular protocol', 'a patent-pending preparation', 'a proprietary enhancement' — that obscures the cellular product's source and processing arc behind a marketing-grade trade-secret framing. The conservative practices articulate the processing protocol within the regulatory framework's register; the practices that retreat into proprietary-claim copy are working at a thinner discipline than the regulatory framework expects.

Patterns to watch for: - Specific cell counts cited without counting methodology or reference range - 'Proprietary' or 'exclusive' processing as a frame that obscures the protocol's source - 'Patent-pending' cellular preparations cited without patent reference - Cellular-product claims that a careful reader cannot map to the published literature

Why it reads as a flag: The cleaner Korean cellular-therapy register articulates the product within the regulatory framework's documentation; copy that performs precision without substantiation is signalling marketing-led rather than laboratory-led practice. The diagnostic question a careful reader should be able to ask — and the conservative practices should be able to answer at the consult — is whether the cellular product's source, processing pathway, quality-control register, and lot identification can be referenced against documents the patient is permitted to read; the directness of the answer is, in itself, part of the reading.

#4 — Before-and-after photography without context

The fourth pattern reads in the practice's photographic register. Before-and-after photography is, on a clean reading, one of the more useful patient-facing tools in aesthetic medicine — but only when the photography is calibrated, contextualised, and disclosed. The conservative Korean practices, where they use the register at all, treat the before-and-after photograph as a clinical document rather than as a marketing image: the lighting is consistent, the angle is calibrated, the post-treatment timepoint is articulated, the indication and protocol are named, the patient's consent and disclosure register are documented, and the photograph is read alongside the protocol's evidence rather than substituted for it. A practice's marketing copy that foregrounds before-and-after photography without these calibrations — without consistent lighting, without the post-treatment timepoint, without the indication framing, without the consent and disclosure register — is, in my reading, doing decorative rather than clinical work. The photographic register is also a Korean Medical Service Act question; the framework treats certain before-and-after registers as regulated matters, and the conservative practices stay well inside the regulatory expectation. A related pattern is the social-media-grade reel that compresses the before-and-after sequence into a five-second cut without any of the calibrations a clinical photograph requires; the reel is, in the conservative reading, marketing copy first and clinical document second.

Patterns to watch for: - Inconsistent lighting, angle, or framing across the before-and-after pair - Post-treatment timepoint omitted or vaguely framed ('after') - Indication and protocol omitted from the photograph's caption - Patient consent and disclosure register absent from the practice's photographic policy

Why it reads as a flag: The cleaner Korean aesthetic-medicine register treats the before-and-after photograph as a calibrated clinical document; copy that foregrounds the photograph without calibration is signalling decorative rather than clinical disposition. A reader's check that travels across the corridor's photography is whether the post-treatment photograph and the pre-treatment photograph share the calibrations a clinical document requires — the same lighting, the same angle, the same makeup-and-styling register, the same camera distance, and the same articulated post-treatment timepoint; a divergence on any of these calibrations reads, more often than not, as a marketing-led rather than clinical-led photographic register.

#5 — 'Stem cell' as a generic marketing label

The fifth pattern reads in the precision — or the absence of precision — with which the marketing copy uses the cellular vocabulary itself. The published regenerative-medicine literature distinguishes carefully between cellular-product categories: autologous mesenchymal stem cells from the patient's own adipose tissue, allogeneic umbilical-cord-derived mesenchymal stem cells, bone-marrow-derived mesenchymal stem cells, induced pluripotent stem cells, and the adjacent cellular categories — exosomes, conditioned media, stromal vascular fraction — that share marketing register with stem cells without sharing cellular identity. A practice's marketing copy that compresses the entire cellular vocabulary into the single word 'stem cells' without articulating the source, the cellular type, the processing arc, and the indication-specific calibration is, on the cleaner reading, performing the cellular register rather than working inside it. The conservative Korean practices treat the cellular-vocabulary precision as routine; the consult conversation should articulate, in the first thirty minutes, exactly which cellular product the protocol uses, why the source matches the indication, and how the published literature reads on the source-indication pair. A practice that retreats to 'stem cells' as a single generic label, or that conflates exosome therapy with stem cell therapy without disclosing the distinction, is working at a register a careful reader should pause over. The distinction matters not only for the patient's clinical understanding but for the regulatory register the protocol sits within; the cellular categories are governed under different framework provisions, and the cleaner copy reflects the framework's distinctions.

Patterns to watch for: - 'Stem cells' used without source, type, or processing-arc articulation - Exosome therapy or conditioned-media therapy framed as 'stem cell therapy' - Cellular vocabulary that does not map to the regulatory framework's categories - Marketing copy that conflates autologous and allogeneic cellular registers

Why it reads as a flag: The cleaner Korean cellular-therapy register articulates the product with vocabulary precision; copy that retreats to the generic label is signalling thinner clinical and regulatory discipline. A practical reader's lens — and one the conservative consult rooms welcome — is to ask the practice, at the first consult, exactly which cellular category the protocol uses, why the source matches the indication, and what the published literature reads on the source-indication pair; a practice that answers cleanly is working in the register the regulatory framework expects.

#6 — Imported scientific authority without citation

The sixth pattern reads in how the marketing copy borrows scientific authority. The conservative Korean medical-aesthetic literature treats citation as a discipline; the cleaner copy names the studies, the journals, the publication years, and the indication framework the cited literature sits within. A practice's marketing copy that gestures at scientific authority — 'studies show', 'research has demonstrated', 'clinical evidence supports' — without naming the studies, without citing the journals, without articulating the indication-specific framework the cited literature applies to, is, in my reading, performing scientific authority rather than substantiating it. A 2023 review in the regenerative-medicine quality-framework literature framed citation discipline as 'the floor of any defensible cellular protocol communication', and the framing reads, in my view, as the correct one. A related pattern is the citation-by-photograph — the marketing image of a journal cover, a laboratory-coat figure with a clipboard, an institutional logo — that performs the scientific register without supplying the citations the register implies. A practice's marketing copy should be readable against the published literature; if a careful reader cannot find the cited evidence in the public record, the copy is doing performative rather than substantive work. The conservative Korean practices write in a register where the citations are nameable; the practices that retreat into ambient scientific authority are working at a register a careful reader should pause over.

Patterns to watch for: - 'Studies show' or 'research demonstrates' without citation - Citation-by-photograph (journal covers, lab-coat imagery) without underlying references - Institutional logos cited without articulating the relationship - Scientific-authority claims that a careful reader cannot verify in the public record

Why it reads as a flag: The cleaner regenerative-medicine register articulates citations the public record can verify; copy that performs scientific authority without substantiation is signalling marketing-led rather than literature-led communication. PubMed's [public regenerative-medicine literature search](https://pubmed.ncbi.nlm.nih.gov/) is the verifiable register a careful reader should be able to read the citations against.

#7 — Pricing copy that obscures the itemisation

The seventh pattern reads in the marketing copy's pricing register. The conservative Korean practices treat pricing as an itemisation — the consult fee, the work-up costs, the cellular product cost, the procedure fee, the post-procedure surveillance arc — and the itemisation reads in the patient-facing quotation as a discipline marker. A practice's marketing copy that compresses the protocol's pricing into a single 'package price' without itemisation, that foregrounds the headline number without disclosing the surcharge framework, that frames the cellular protocol as an inclusive flat rate without articulating the work-up and surveillance costs that sit alongside the procedure, is, in my reading, working at a register a careful reader should pause over. A related pattern is the limited-time-offer register — the discount banner, the seasonal-promotion graphic, the package-deal framing — that imports retail marketing logic into a clinical-protocol context. The cleaner Korean cellular-therapy practices do not run discount promotions; the indication and the work-up determine the protocol's structure, and the structure determines the cost. A practice that runs the cellular protocol on a retail-marketing calendar is, on the conservative reading, signalling marketing-led rather than indication-led practice. The same reading applies to financing-led copy that foregrounds payment-plan availability over indication framework — the financing register is a procedural fact rather than a marketing centre, and the cleaner copy treats it that way.

Patterns to watch for: - 'Package price' framing without line-item disclosure - Limited-time-offer or seasonal-promotion register on cellular protocols - Financing-plan copy foregrounded over indication and protocol framing - Surcharge frameworks (foreign-patient, agency-referral) absent from the headline copy

Why it reads as a flag: The cleaner Korean cellular-therapy register treats pricing as an itemisation; copy that retreats to the package-price register or the discount-promotion calendar is signalling retail-marketing rather than clinical-protocol disposition.

#8 — Aggressive urgency and scarcity messaging

The eighth pattern reads in the marketing copy's temporal register. Cellular therapy is — in the conservative Korean register, and in the cleaner regenerative-medicine literature broadly — a paced intervention. The work-up takes time, the consult arc takes time, the protocol's scheduling sits inside a calibrated framework rather than inside a retail-grade urgency calendar. A practice's marketing copy that foregrounds urgency — 'limited slots available', 'only three openings this month', 'book before prices increase' — is, in my reading, importing retail-conversion logic into a clinical context where the conversion logic does not belong. A related pattern is the scarcity register that frames the cellular product itself as scarce — 'limited supply of cellular preparations', 'last batch available' — without articulating the regulatory or laboratory framework that would underwrite the scarcity claim. The conservative Korean practices write in the register of paced consultation; the consult arc is calibrated to the indication rather than to the practice's quarterly calendar. A practice that compresses the consult arc into a same-day urgency frame, that runs countdown timers on the booking page, that frames the patient's hesitation as a missed opportunity, is working at a register a careful reader should pause over. The pause is itself a clinical disposition; the cleaner consult rooms welcome the pause, and the practices that erode the pause are signalling something the consult conversation should confirm or refute.

Patterns to watch for: - 'Limited time' or 'only X slots' urgency on cellular protocols - Countdown timers on booking or consult-scheduling interfaces - Scarcity claims on cellular products without regulatory or laboratory grounding - Marketing copy that frames patient hesitation as a missed-opportunity register

Why it reads as a flag: The cleaner Korean cellular-therapy register treats consultation as paced; copy that imports retail-urgency logic is signalling conversion-led rather than indication-led practice.

#9 — Unscoped indication claims and condition lists

The ninth pattern reads in how broadly the marketing copy claims the cellular protocol's indication scope. The conservative regenerative-medicine literature treats indication scope as a discipline; the cellular product, the source, the processing arc, and the published evidence base together delimit the indications the protocol is calibrated for, and the cleaner copy articulates those delimitations. A practice's marketing copy that lists an unscoped sweep of conditions — chronic fatigue, autoimmune disease, anti-ageing, hair restoration, sexual wellness, neurological conditions, cardiovascular conditions, and a longer list besides, all framed as cellular-protocol indications — is, in my reading, working under thinner indication discipline than the regulatory framework or the published literature support. The unscoped condition list is one of the more diagnostic patterns; the cleaner copy is calibrated to the indications the published literature supports for the cellular product in question, and the louder copy expands the indication list past what the literature underwrites. A related pattern is the 'cure for ageing' register, or the longevity-medicine register that compresses cellular therapy into a generic anti-ageing claim without articulating the indication-specific framework. Korean medical-tourism law treats certain unscoped condition claims as regulated matters under the Medical Service Act; the conservative practices stay well inside the regulatory framework, and the practices that drift past it are signalling something a careful reader should attend to. The Korean [Ministry of Food and Drug Safety register](https://www.mfds.go.kr/eng/index.do) of registered cellular-therapy indications is the public record against which a careful reader should be able to map the practice's indication claims.

Patterns to watch for: - Unscoped condition lists that span cellular-protocol indications across body systems - 'Cure for ageing' or longevity-medicine framing without indication-specific calibration - Indication claims that do not map to the regulatory framework's registered scope - Cellular-protocol claims for conditions the published literature does not support

Why it reads as a flag: The cleaner regenerative-medicine register articulates indication scope with discipline; copy that expands the indication list past the regulatory and literature register is signalling marketing-led rather than indication-led practice.

#10 — Absence of risk, contraindication, and adverse-event copy

The tenth pattern is the quietest and, on a careful reading, perhaps the most diagnostic. Cellular therapy is — even at its cleanest, even within the regulatory framework's tightest calibration — an intervention with a defined risk profile, a defined contraindication framework, and a defined adverse-event register. The conservative Korean practices articulate these registers on their patient-facing materials as routine; the consent document, the consult conversation, and the practice's editorial pages all read the risk register openly. A practice's marketing copy that compresses the protocol into benefit-only register — without contraindications, without adverse-event disclosure, without the risk profile the cellular protocol carries even in its cleaner application — is, in my reading, working at a register that erases the protocol's clinical reality. The absence is the marker. The cleaner Gangnam consult rooms read calmly partly because they hold the risk register openly; the practices that retreat to benefit-only marketing are working at a register a careful reader should attend to with particular care. 風險都要寫埋出嚟, as the Cantonese phrasing has it — the risks should be written out as well. The discipline of disclosure is the discipline of the protocol; the practices that sustain the disclosure are the practices that have absorbed the regulatory and clinical framework most fully. A patient who arrives at the consult having read only benefit-register copy is in a thinner conversation than the protocol requires; a patient who arrives having read the risk register, the contraindication framework, and the adverse-event disclosure is in the consult conversation the conservative Korean practices most welcome.

Patterns to watch for: - Benefit-only marketing copy without risk, contraindication, or adverse-event disclosure - Consent documents that compress the risk register into a procedural-permission form - Editorial pages that articulate the protocol's mechanism without its risk profile - Marketing copy that frames the cellular protocol as risk-free or near-risk-free

Why it reads as a flag: The conservative Korean cellular-therapy register treats risk disclosure as protocol-defining; copy that erases the risk register is signalling marketing-led rather than clinical disposition. The practice's relationship to its own risk register is one of the more diagnostic windows into its broader clinical discipline.

Comparison table — the ten patterns, side by side

The categorical comparison below summarises the ten patterns across the register they belong to, the framework they depart from, and the reading lens a careful patient should hold them under. The table is offered as a categorical framework rather than as a checklist against any specific practice; no clinic is named, and no clinic is positioned against another. Patients should treat the table as a reading lens for the marketing copy they encounter rather than as a screening tool against a particular practice.

Editorial note — how to use the field guide

The list is a reading lens for the marketing copy a patient encounters rather than a screening tool against any specific practice, and the distinction is the editorial spine of the piece. No practice's marketing copy will read uniformly clean across all ten patterns; the conservative reading is to weight patterns one, three, five, eight, nine, and ten — the patterns that most directly intersect with the regulatory framework and the protocol's clinical discipline — as the most diagnostic, and to read the remaining four as the texture against which the practice's marketing-led versus indication-led disposition becomes legible. A reader who arrives at the consult with the ten patterns internalised is reading the marketing copy the way the conservative Korean practices write it — slowly, sceptically, with attention to the seams. A reader who reads only the headline copy, only the celebrity register, only the package-price banner, is in a thinner conversation than the protocol requires. The cleaner consult rooms read calmly. The framework is meant to read calmly with them. The list does not, and is not intended to, name a clinic to avoid; it is a reading discipline rather than a screening directive. 慢慢諗清楚先做決定, as the Cantonese phrasing has it — work it through carefully, and then decide. The slower decision is, by some distance, the better one. Patients should treat the ten patterns as the framework's spine and the consult conversation as the framework's stress test; the practices whose marketing copy reads cleanly across the patterns, and whose consult rooms sustain the cleanness in conversation, are the ones that have built the institutional discipline a careful patient should value.

Frequently asked questions

Is this list a screening tool against specific clinics?

No, and the editorial register is intentional. The ten patterns are categorical rather than directed; no clinic is named, and no clinic is positioned against another. Korean medical-tourism law (Article 56(4) of the Medical Service Act) treats direct ranking and named comparison of healthcare providers in foreign-patient contexts as a regulated matter, and the editorial register here is calibrated accordingly. The list is a reading lens for the marketing copy a patient encounters across any practice, rather than a screening directive against a particular practice.

If a practice's copy shows one of these patterns, should I rule it out?

The reading depends on which pattern, and on whether the consult conversation confirms or refutes the marketing-copy reading. A pattern in the marketing copy is a reason to pause and read more carefully; it is not, on its own, a sufficient reason to rule a practice out. The conservative reading is to treat patterns one, three, five, eight, nine, and ten as the most diagnostic, and to bring the relevant questions into the consult conversation directly. The practice's response to the questions is itself part of the reading.

How can I verify a practice's cellular-therapy claims against the regulatory framework?

The Korean Ministry of Food and Drug Safety maintains a publicly accessible register of cellular-therapy products and registered indications. A careful reader can request the practice's registration reference, verify it against the public register, and read the practice's indication claims against the framework's registered scope. The conservative practices treat the verification as routine; the practices that soften the verification question are signalling something a careful reader should attend to.

What about exosome therapy and stromal vascular fraction — are these stem cells?

They are adjacent cellular categories rather than stem cells in the strict sense. Exosomes are extracellular vesicles released by cells; stromal vascular fraction is a heterogeneous cellular preparation derived from adipose tissue that contains mesenchymal stem cells alongside other cellular populations. The published literature distinguishes the categories carefully, and the regulatory framework governs them under different provisions. Marketing copy that conflates the categories — framing exosome therapy as 'stem cell therapy', or stromal vascular fraction as 'pure stem cells' — is one of the patterns the field guide flags as a precision concern.

Are celebrity endorsements always a red flag?

Not categorically. The pattern is the absence of disclosure, not the presence of the celebrity register itself. A practice that articulates the commercial relationship that underwrites a celebrity endorsement, that names the indication and protocol the celebrity was treated for, and that sustains the endorsement within the Korean Fair Trade Commission's disclosure framework is reading the celebrity register in the cleaner register. The flag rises when the disclosure is absent, when the relationship is obscured, or when the celebrity testimony is performed as untreated patient testimony.

How should I read the 'limited-time offer' copy if a practice is genuinely running a promotion?

The conservative Korean cellular-therapy register treats clinical protocols as protocol-led rather than promotion-led; the indication and the work-up determine the protocol's structure, and the structure does not run on a retail-marketing calendar. A practice that runs limited-time-offer copy on cellular protocols is, on the conservative reading, importing retail-conversion logic into a clinical context where the logic does not belong. The pattern reads as a flag regardless of the practice's underlying intent; the cleaner cellular-therapy register does not run promotional calendars on the protocol itself, even where the practice may run them on adjacent non-protocol services.

What if I cannot verify the citations in a practice's marketing copy?

The cleaner regenerative-medicine register articulates citations the public record can verify — PubMed-indexed journals, named studies, articulated publication years, indication-specific framings. A careful reader should be able to take the practice's citations to the public PubMed search and find the cited studies; if the citations cannot be verified, the copy is doing performative rather than substantive scientific work. The pattern reads as a flag, and the consult conversation is the appropriate place to bring the verification question directly.

Does the absence of risk copy mean the practice is hiding something?

It means the practice's marketing copy is working in a benefit-only register, and the register itself is the flag. The conservative Korean practices articulate the protocol's risk profile, contraindication framework, and adverse-event register on their patient-facing materials as routine; the practices that compress the protocol into benefit-only register are working at a register a careful reader should attend to. Whether the absence reflects active concealment or thinner clinical discipline is a question for the consult conversation and the consent document, both of which the conservative practices treat as the appropriate place for the risk register to read in full.